.png){kind=icon}
.png){kind=icon}
Return
Real-World Use of Evinacumab at the University of Pennsylvania Health Systems
.png){kind=icon}
PRE
AI
M
R
A
DOI：10.1016/j.jacl.2026.05.191.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Evinacumab is a monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3) that reduces low-density lipoprotein cholesterol (LDL-C) levels by ~50% when used with standard lipid-lowering therapies in homozygous familial hypercholesterolemia (HoFH) patients. Food and Drug Administration (FDA) approved in February 2021, it is administered via monthly intravenous infusions.
Journal
IF:
4.6
Papers:
2.5K
Citations:
4.3K
Organization
No organization information available
Cited Papers